By Julie Steenhuysen CHICAGO (Reuters) – A large study sponsored by privately held Guardant Health Inc of California showed that its Guardant360 liquid biopsy test, which looks at bits of tumor DNA in blood samples, closely mirrored the cancer genes taken from traditional tissue biopsies. The findings, presented on Saturday at the American Society of Clinical Oncology meeting in Chicago, suggest that blood tests might be a suitable alternative in some cases to tissue biopsies for guiding treatment decisions. Doctors increasingly have been using tissue biopsies – tiny bits of tumors removed surgically from patients – to determine which genes are driving the growth of cancers.
See the rest here:
Large Guardant Health study backs use of ‘liquid biopsies’
